Details of the Drug

General Information of Drug (ID: DMDI269)

Drug Name

Docetaxel

Synonyms

EmDOC; TXL; Taxotere; Docetaxel anhydrous; ANX-514; Docetaxel (INN); Docetaxel, Trihydrate; RP-56976; SDP-014; Taxotere (TN); Taxotere(R); XRP-6976L; Docetaxel 114977-28-5; N-debenzoyl-N-Boc-10-deacetyl taxol; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[1]
Breast carcinoma	N.A.	Approved	[1]
Head and neck cancer	2D42	Approved	[1]
Leiomyosarcoma	2B58	Approved	[1]
Lung cancer	2C25.0	Approved	[1]
Non-small-cell lung cancer	2C25.Y	Approved	[1]
Prostate adenocarcinoma	N.A.	Approved	[1]
Prostate cancer	2C82.0	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Urinary system neoplasm	N.A.	Approved	[1]
Gastric cancer	2B72	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 3

Molecular Weight (mw)

807.9

Logarithm of the Partition Coefficient (xlogp)

1.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 14 mL/min/kg [4]
Elimination: 5% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 4 minutes (alpha), 36 minutes (beta), and 11.1 hours (gamma) [4]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.1457 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.04% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.1 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 0.0065 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Leukopenia	rs12762549	ABCC2	OTJSIGV5	[6]
-----------

Chemical Identifiers

Formula: C43H53NO14
IUPAC Name: [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
Canonical SMILES: CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
InChI: InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
InChIKey: ZDZOTLJHXYCWBA-VCVYQWHSSA-N

Cross-matching ID

PubChem CID: 148124
ChEBI ID: CHEBI:4672
CAS Number: 114977-28-5
DrugBank ID: DB01248
TTD ID: D0O5WP
VARIDT ID: DR00251
INTEDE ID: DR0520
ACDINA ID: D01011

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin (TUB)	TTML2WA	NOUNIPROTAC	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
TAP-like protein (ABCB9)	DT68UV2	ABCB9_HUMAN	Substrate	[8]
Multidrug resistance-associated protein 7 (ABCC10)	DTPS120	MRP7_HUMAN	Substrate	[9]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[10]
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[11]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[12]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[13]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[14]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[16]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[17]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[17]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Gene/Protein Processing	[18]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[19]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[20]
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Gene/Protein Processing	[21]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Drug Response	[6]
ATP-binding cassette sub-family C member 6 (ABCC6)	OTZT0LKT	MRP6_HUMAN	Drug Response	[22]
ATP-binding cassette sub-family G member 1 (ABCG1)	OT5BG6MK	ABCG1_HUMAN	Drug Response	[22]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Drug Response	[23]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Drug Response	[24]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Gene/Protein Processing	[25]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification

02 Neoplasm

Disease Class

ICD-11: 2C82 Prostate cancer

The Studied Tissue

Lung tissue

The Studied Disease

Lung cancer [ICD-11:2C82]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tubulin (TUB)	DTT	NO-GeName	5.46E-09	0.28	0.72
P-glycoprotein 1 (ABCB1)	DTP	P-GP	3.12E-33	-8.30E-01	-1.04E+00
Multidrug resistance-associated protein 1 (ABCC1)	DTP	MRP1	1.90E-30	1.76E-01	7.31E-01
Multidrug resistance-associated protein 7 (ABCC10)	DTP	MRP7	2.34E-47	4.95E-01	1.54E+00
Breast cancer resistance protein (ABCG2)	DTP	BCRP	3.87E-47	-1.28E+00	-1.63E+00
Multidrug resistance-associated protein 2 (ABCC2)	DTP	MRP2	1.02E-08	-5.12E-02	-2.22E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DTP	OATP1B3	3.46E-61	1.83E-01	7.90E-01
TAP-like protein (ABCB9)	DTP	TAPL	2.04E-01	4.47E-02	1.45E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DTP	OATP1B1	2.80E-34	1.44E-01	9.71E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	3.12E-38	-1.81E+00	-2.01E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	5.59E-39	-3.76E-01	-1.64E+00

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Docetaxel

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Docetaxel caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[26]
Armodafinil	DMGB035	Minor	Increased metabolism of Docetaxel caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[27]
LEE011	DMMX75K	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by LEE011.	Solid tumour/cancer [2A00-2F9Z]	[26]
-----------

Coadministration of a Drug Treating the Disease Different from Docetaxel (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Docetaxel caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[26]
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[28]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Docetaxel caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[26]
Gilteritinib	DMTI0ZO	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[29]
Dronedarone	DMA8FS5	Major	Decreased clearance of Docetaxel due to the transporter inhibition by Dronedarone.	Angina pectoris [BA40]	[26]
Posaconazole	DMUL5EW	Major	Decreased clearance of Docetaxel due to the transporter inhibition by Posaconazole.	Aspergillosis [1F20]	[26]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Docetaxel and Roflumilast.	Asthma [CA23]	[28]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Docetaxel caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[26]
ABT-492	DMJFD2I	Minor	Decreased absorption of Docetaxel due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[30]
Troleandomycin	DMUZNIG	Major	Decreased clearance of Docetaxel due to the transporter inhibition by Troleandomycin.	Bacterial infection [1A00-1C4Z]	[26]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[31]
Lapatinib	DM3BH1Y	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Lapatinib.	Breast cancer [2C60-2C6Y]	[26]
Tucatinib	DMBESUA	Major	Decreased clearance of Docetaxel due to the transporter inhibition by Tucatinib.	Breast cancer [2C60-2C6Y]	[26]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Docetaxel caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[26]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Docetaxel caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[26]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[26]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Docetaxel caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[26]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Docetaxel caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Stiripentol	DMMSDOY	Major	Decreased metabolism of Docetaxel caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Docetaxel caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Docetaxel caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Docetaxel caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Boceprevir	DMBSHMF	Major	Decreased clearance of Docetaxel due to the transporter inhibition by Boceprevir.	Hepatitis virus infection [1E50-1E51]	[26]
Simeprevir	DMLUA9D	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Simeprevir.	Hepatitis virus infection [1E50-1E51]	[26]
Telaprevir	DMMRV29	Major	Decreased clearance of Docetaxel due to the transporter inhibition by Telaprevir.	Hepatitis virus infection [1E50-1E51]	[26]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Docetaxel and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[32]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Docetaxel caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Cobicistat	DM6L4H2	Major	Decreased clearance of Docetaxel due to the transporter inhibition by Cobicistat.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Docetaxel caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Docetaxel caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Docetaxel and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[33]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[29]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Docetaxel caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[26]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Docetaxel caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[26]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Docetaxel and Denosumab.	Low bone mass disorder [FB83]	[34]
Crizotinib	DM4F29C	Major	Decreased clearance of Docetaxel due to the transporter inhibition by Crizotinib.	Lung cancer [2C25]	[26]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Docetaxel caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[35]
Ceritinib	DMB920Z	Major	Decreased metabolism of Docetaxel caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[26]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Docetaxel caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[26]
Osimertinib	DMRJLAT	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Osimertinib.	Lung cancer [2C25]	[26]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[36]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Docetaxel caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[26]
Idelalisib	DM602WT	Major	Decreased metabolism of Docetaxel caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[26]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Docetaxel caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[26]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Docetaxel caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[26]
LGX818	DMNQXV8	Moderate	Increased metabolism of Docetaxel caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[37]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Docetaxel caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[26]
Danazol	DML8KTN	Moderate	Decreased metabolism of Docetaxel caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[26]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[38]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Docetaxel caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[39]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Docetaxel and Tecfidera.	Multiple sclerosis [8A40]	[40]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Docetaxel and Siponimod.	Multiple sclerosis [8A40]	[29]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Docetaxel and Fingolimod.	Multiple sclerosis [8A40]	[41]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Docetaxel and Ocrelizumab.	Multiple sclerosis [8A40]	[42]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Docetaxel and Ozanimod.	Multiple sclerosis [8A40]	[28]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Docetaxel caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[26]
Dasatinib	DMJV2EK	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Dasatinib.	Myeloproliferative neoplasm [2A20]	[26]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Docetaxel and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[43]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[44]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Docetaxel caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[26]
Entrectinib	DMMPTLH	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Entrectinib.	Non-small cell lung cancer [2C25]	[26]
Rucaparib	DM9PVX8	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Rucaparib.	Ovarian cancer [2C73]	[26]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Docetaxel caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[45]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Docetaxel caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[46]
Lonafarnib	DMGM2Z6	Major	Decreased clearance of Docetaxel due to the transporter inhibition by Lonafarnib.	Premature ageing appearance [LD2B]	[26]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Docetaxel caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[26]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Docetaxel and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[47]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Docetaxel and Canakinumab.	Rheumatoid arthritis [FA20]	[48]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Docetaxel and Rilonacept.	Rheumatoid arthritis [FA20]	[48]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Docetaxel and Golimumab.	Rheumatoid arthritis [FA20]	[49]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Docetaxel when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[50]
Voxelotor	DMCS6M5	Moderate	Decreased clearance of Docetaxel due to the transporter inhibition by Voxelotor.	Sickle-cell disorder [3A51]	[26]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Docetaxel caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[28]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Docetaxel caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[51]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Docetaxel caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[26]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Docetaxel and Valganciclovir.	Virus infection [1A24-1D9Z]	[29]
-----------


⏷ Show the Full List of 76 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Ethanol	E00023	702	Antimicrobial preservative; Penetration agent; Solvent
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Docetaxel 20mg/2ml injectable	20mg/2ml	Injectable	Injection
Docetaxel 80mg/4ml injectable	80mg/4ml	Injectable	Injection
Docetaxel 160mg/8ml injectable	160mg/8ml	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Docetaxel FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6809).
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May;99(5):967-72.
7	Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
8	RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel. Mol Biosyst. 2017 Sep 26;13(10):2125-2134.
9	Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
10	Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
11	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
12	Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
13	FDA Drug Development and Drug Interactions
14	Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
15	Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6.
16	Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 2005 Feb 20;23(6):1061-9.
17	Drug Interactions Flockhart Table
18	Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Biochem Pharmacol. 2011 Nov 1;82(9):1100-9. doi: 10.1016/j.bcp.2011.07.078. Epub 2011 Jul 23.
19	Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy. J Oral Pathol Med. 2005 Feb;34(2):93-9. doi: 10.1111/j.1600-0714.2004.00257.x.
20	Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
21	Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers. Clin Cancer Res. 2004 Dec 15;10(24):8163-9.
22	Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS. 2013 Jul;17(7):353-67. doi: 10.1089/omi.2013.0019. Epub 2013 Jun 11.
23	Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
24	[Antisense RNA targeting survivin enhances the chemosensitivity of LOVO/Adr cells to taxotere]. Zhonghua Wei Chang Wai Ke Za Zhi. 2005 Sep;8(5):455-8.
25	Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res. 2007 Feb 15;13(4):1308-14. doi: 10.1158/1078-0432.CCR-06-2216.
26	Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
27	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
28	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
29	Cerner Multum, Inc. "Australian Product Information.".
30	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
31	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
32	Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
33	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
34	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
35	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
36	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
37	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
38	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
39	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
40	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
41	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
42	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
43	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
44	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
45	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
46	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
47	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
48	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
49	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
50	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
51	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.